Roth Capital’s healthcare analyst Michael Higgins weighed in with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), after hosting an investor meeting with a Key Opinion Leader, Dr. Richard Drachtman, who treats ~450 sickle cell patients at the Rutgers Cancer Institute of New Jersey, based in Newark.

Higgins wrote, “Dr. Drachtman noted that the rate of his SC patients on HU has risen steadily over the past few years, to ~70% today. Two weeks ago, we learned at Mast’s 4th Annual SC conference that another Ped Hem/Onc, Dr. Julie KanterWashko, from the University of South Carolina, estimated that 50% of her ~400 SC patients were on HU, up from her comments a year prior of 30% on HU”

“We believe Dr. Drachtman is one of the biggest enrolling physicians in Mast’s EPIC trial. While anecdotal and generalized, his comments were in our view supportive of EPIC’s outcome,” the analyst added.

Higgins reiterated a Buy rating on shares of Mast Therapeutics, with a price target of $3.00, which represents a potential upside of 574% from where the stock is currently trading.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Michael Higgins has a total average return of 17.4% and a 57.1% success rate. Higgins has a -9.4% average return when recommending MSTX, and is ranked #698 out of 3771 analysts.

All the 4 analysts polled by TipRanks rate Mast Therapeutics stock a Buy. With a return potential of 424%, the stock’s consensus target price stands at $2.33.

MSTX Chart